Serum paraoxonase activity in uremic predialysis and hemodialysis patients

Simple item page
dc.contributor.buuauthorDirican, Melahat
dc.contributor.buuauthorAkça, Ramazan
dc.contributor.buuauthorSarandöl, Emre
dc.contributor.buuauthorDilek, Kamil
dc.contributor.departmentUludağ Üniversitesi/Tıp Fakültesi/Nefroloji Bilim Dalı.tr_TR
dc.contributor.departmentUludağ Üniversitesi/Tıp Fakültesi/Tıbbi Biyokimya Anabilim Dalı.tr_TR
dc.contributor.orcid0000-0002-2593-7196tr_TR
dc.contributor.researcheridABE-1716-2020tr_TR
dc.date.accessioned2021-07-06T08:06:23Z
dc.date.available2021-07-06T08:06:23Z
dc.date.issued2004-11
dc.description.abstractBackground: Paraoxonase (PON1) is a high-density lipoprotein (HDL)-associated enzyme and has been shown to reduce the susceptibility of low-density lipoprotein (LDL) to lipid peroxidation. This study aimed to investigate the activity and phenotype distribution of serum paraoxonase in uremic patients, and to evaluate the correlations of uremia-associated substances (urea, creatinine (Cr) and uric acid) with paraoxonase activity. Methods: Twenty-eight patients with chronic renal failure (CRF), 44 patients with CRF undergoing hemodialysis (HD) and 26 healthy controls were included in this study. Paraoxon or phenylacetate was used as a substrate for measuring paraoxonase and arylesterase activity, respectively. The double substrate method was used to assign phenotypes. Serum lipid parameters were determined by routine laboratory methods. Results: Paraoxonase activity, HDL-cholesterol and apolipoprotein (apo) AI levels were found to be significantly lower in HD patients than in controls. However, HDL-standardized paraoxonase activity (PON activity/HDL) was not different in the HD patients compared to controls. Arylesterase activity was significantly lower in both CRF and HD patients than in controls. Paraoxonase phenotype distribution was not different among the groups according to the double substrate method. Serum paraoxonase and arylesterase activities correlated inversely with serum urea and Cr levels. Conclusion: Patients on long-term HD have reduced paraoxonase/arylesterase activities and this could be related to reduced HDI-cholesterol and apo AI levels, as well as increased urea and Cr levels in uremia.en_US
dc.identifier.citationDirican, M. vd. (2004). “Serum paraoxonase activity in uremic predialysis and hemodialysis patients”. Journal of Nephrology, 17(6), 813-818.tr_TR
dc.identifier.endpage818tr_TR
dc.identifier.issn1121-8428
dc.identifier.issue6tr_TR
dc.identifier.pubmed15593056tr_TR
dc.identifier.scopus2-s2.0-16644391990tr_TR
dc.identifier.startpage813tr_TR
dc.identifier.urihttps://pubmed.ncbi.nlm.nih.gov/15593056/
dc.identifier.urihttp://hdl.handle.net/11452/21108
dc.identifier.volume17tr_TR
dc.identifier.wos000225744100011tr_TR
dc.indexed.pubmedPubmeden_US
dc.indexed.scopusScopusen_US
dc.indexed.wosSCIEen_US
dc.language.isoenen_US
dc.publisherWichtig Editoreen_US
dc.relation.journalJournal of Nephrologytr_TR
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergitr_TR
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectParaoxonaseen_US
dc.subjectHemodialysisen_US
dc.subjectUremiaen_US
dc.subjectHigh-density lipoproteinen_US
dc.subjectChronic-renal-failureen_US
dc.subjectCardiovascular-diseaseen_US
dc.subjectOxidative modificationen_US
dc.subjectPeritoneal-dialysisen_US
dc.subjectMolecular-basisen_US
dc.subjectArylesteraseen_US
dc.subjectAtherosclerosisen_US
dc.subjectPolymorphismen_US
dc.subjectRisken_US
dc.subjectUrology & nephrologyen_US
dc.subject.wosUrology & nephrologyen_US
dc.titleSerum paraoxonase activity in uremic predialysis and hemodialysis patientsen_US
dc.typeArticle
dc.wos.quartileQ3en_US

Files

License bundle
Now showing 1 - 1 of 1
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

Web of Science